BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.

Sci Rep 2015 Dec 7;5:17499. Epub 2015 Dec 7.

Instituto Oncológico Dr Rosell, Quiron-Dexeus University Hospital, Barcelona, Spain.

BIM is a proapoptotic protein that initiates apoptosis triggered by EGFR tyrosine kinase inhibitors (TKI). mTOR negatively regulates apoptosis and may influence response to EGFR TKI. We examined mRNA expression of BIM and MTOR in 57 patients with EGFR-mutant NSCLC from the EURTAC trial. Risk of mortality and disease progression was lower in patients with high BIM compared with low/intermediate BIM mRNA levels. Analysis of MTOR further divided patients with high BIM expression into two groups, with those having both high BIM and MTOR experiencing shorter overall and progression-free survival to erlotinib. Validation of our results was performed in an independent cohort of 19 patients with EGFR-mutant NSCLC treated with EGFR TKIs. In EGFR-mutant lung adenocarcinoma cell lines with high BIM expression, concomitant high mTOR expression increased IC50 of gefitinib for cell proliferation. We next sought to analyse the signalling pattern in cell lines with strong activation of mTOR and its substrate P-S6. We showed that mTOR and phosphodiesterase 4D (PDE4D) strongly correlate in resistant EGFR-mutant cancer cell lines. These data suggest that the combination of EGFR TKI with mTOR or PDE4 inhibitors could be adequate therapy for EGFR-mutant NSCLC patients with high pretreatment levels of BIM and mTOR.

Download full-text PDF

Source
http://dx.doi.org/10.1038/srep17499DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671004PMC
December 2015
96 Reads
14 Citations
5.080 Impact Factor

Publication Analysis

Top Keywords

bim mtor
16
high bim
16
egfr-mutant nsclc
12
cell lines
12
patients high
12
mtor
9
bim
9
tki mtor
8
patients egfr-mutant
8
egfr tki
8
bim expression
8
mtor expression
8
high
6
egfr-mutant
6
patients
5
expression
5
egfr tkis
4
independent cohort
4
treated egfr
4
cohort patients
4

References

(Supplied by CrossRef)

R Rosell et al.
The lancet oncology 2012

TS Mok et al.
The New England journal of medicine 2009

R Rosell et al.
Lancet 2013

LV Sequist et al.
Science translational medicine 2011

AC Faber et al.
Cancer discovery 2011

A Letai et al.
Cancer cell 2002

DB Costa et al.
PLoS medicine 2007

C Costa et al.
Clinical cancer research : an official journal of the American Association for Cancer Research 2014

RB Corcoran et al.
Science translational medicine 2013

M Laplante et al.
Cell 2012

HE Thomas et al.
Science translational medicine 2012

Similar Publications